AstraZeneca PLC
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca Respiratory & Immunology (R&I) by Year
Respiratory & Immunology (R&I) — Europe product sales ($M) ($M)
AstraZeneca Respiratory & Immunology (R&I): $1,701M in FY2025, up 20.1% from a year earlier.
Where the FY2025 figure comes from
“|| R&I | 8,167 | 10 | 10 | 3,840 | 12 | 1,823 | (4) | (3) | 1,701 | 20 | 16 | 803 | 17 | 18”
Source: Form 6-K FY2025Q4 Earnings Release ↗
Reported in Form 6-K / 20-F Therapy Area Product Sales Table.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Respiratory & Immunology (R&I) — Europe product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,701 | +20.1% | Form 6-K FY2025Q4 Earnings Release ↗ |
| FY2024 | Dec 31, 2024 | 1,416 | +21.6% | Form 6-K FY2024Q4 Earnings Release ↗ |
| FY2023 | Dec 31, 2023 | 1,164 | +10.4% | Form 6-K FY2023Q4 Earnings Release ↗ |
| FY2022 | Dec 31, 2022 | 1,054 | -15.5% | Form 6-K FY2022Q4 Earnings Release ↗ |
| FY2021 | Dec 31, 2021 | 1,247 | +6.5% | Form 6-K FY2021Q4 Earnings Release ↗ |
| FY2020 | Dec 31, 2020 | 1,171 | – | Form 6-K FY2020Q4 Earnings Release ↗ |
Breakdown
What makes up respiratory & Immunology (R&I)
Cite this data
StockData. (2026). AstraZeneca Respiratory & Immunology (R&I) ($M), annual FY2020–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/ta-ri-eu
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.